


CLAIMS

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R¹ represents -C₁₋₆ alkyl-O-C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heterocyclyl, heteroaryl, -C₁₋₆ alkyl-aryl, -C₁₋₆ alkyl-heteroaryl, -C₁₋₆ alkyl-heterocyclyl, -aryl-X-aryl, -aryl-X-heteroaryl, -aryl-X-heterocyclyl, -heteroaryl-X-aryl, -heteroaryl-X-heteroaryl, -heteroaryl-X-heterocyclyl, -heterocyclyl-X-aryl, -heterocyclyl-X-heteroaryl or -heterocyclyl-X-heterocyclyl,

wherein said C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl, heteroaryl and heterocyclyl groups of R¹ may be optionally substituted by one or more (eg. 1, 2 or 3) substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, oxo, haloC₁₋₆ alkyl, polyhaloC₁₋₆ alkyl, haloC₁₋₆ alkoxy, polyhaloC₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkoxyC₁₋₆ alkyl, C₃₋₇ cycloalkylC₁₋₆ alkoxy, C₁₋₆ alkanoyl, C₁₋₆ alkoxy carbonyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyloxy, C₁₋₆ alkylsulfonylC₁₋₆ alkyl, C₁₋₆ alkylsulfonylamidoC₁₋₆ alkyl, C₁₋₆ alkylamidoC₁₋₆ alkyl, arylsulfonyl, arylsulfonyloxy, aryloxy, arylsulfonylamido, arylcarboxamido, aroyl, or a group NR¹⁵R¹⁶, -CONR¹⁵R¹⁶, -NR¹⁵COR¹⁶, -NR¹⁵SO₂R¹⁶ or -SO₂NR¹⁵R¹⁶, wherein R¹⁵ and R¹⁶ independently represent hydrogen or C₁₋₆ alkyl or together form a heterocyclic ring;

X represents a bond, O, CO, OCH₂, CH₂O or SO₂;

Z represents CO, CONR¹⁰ or SO₂;

R¹⁰ represents hydrogen, C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, aryl, heterocyclyl, heteroaryl;


----- represents a single or a double bond;

m and n independently represent 0, 1 or 2;

R² represents hydrogen, C₁₋₆ alkyl or C₁₋₆ alkoxy;

R³ represents halogen, C₁₋₆ alkyl, hydroxy, C₁₋₆ alkoxy, cyano, amino, -COC₁₋₆ alkyl, -SO₂C₁₋₆ alkyl or trifluoromethyl;

R⁴ represents -(CH₂)_q-NR¹¹R¹² or a group of formula (i):



wherein q is 2, 3 or 4;

-NR¹¹R¹² represents a heterocyclic group optionally substituted by one or more (eg. 1, 2 or 3) R¹⁷ groups;

R¹³ represents C₁₋₆ alkyl, C₃₋₈ cycloalkyl, -C₁₋₆ alkyl-C₁₋₆ alkoxy, -C₁₋₆ alkyl-C₃₋₈ cycloalkyl; R¹⁴ and R¹⁷ independently represent halogen, C₁₋₆ alkyl, haloalkyl, OH or C₁₋₆ alkoxy;

f is 0 or 1;
 g is 1 or 2
 k is 0, 1 or 2
 or a pharmaceutically acceptable salt thereof.

5

2. A compound as defined in claim 1 wherein R¹ represents:
 -aryl optionally substituted by 1 or 2 halogen, haloC₁₋₆ alkyl, cyano or SO₂Me groups;
 -aryl-X-heterocyclyl;
 10 -heteroaryl optionally substituted by 1 or 2 haloC₁₋₆ alkyl or cyano groups;
 -heterocyclyl optionally substituted by 1 or 2 oxo groups; or
 -C₁₋₆ alkyl-O-C₁₋₆ alkyl.

15

3. A compound as defined in claim 2 wherein R¹ represents tetrahydropyranyl, 4-cyanophenyl, 2-cyanopyridin-3-yl or 2-trifluoromethylpyridin-3-yl.

4. A compound as defined in claim 3 wherein R¹ represents 4-cyanophenyl.

5. A compound as defined in any one of claims 1 to 4 wherein X and Z both represent CO.

20

6. A compound as defined in any one of claims 1 to 5 wherein --- represents a single bond.

7. A compound as defined in any one of claims 1 to 6 wherein m and n both represent 0.

25

8. A compound as defined in any one of claims 1 to 7 wherein R⁴ represents - (CH₂)_q-NR¹¹R¹², q represents 3 and -NR¹¹R¹² represents N-piperidiny or N-pyrrolidiny optionally substituted by 1 or 2 C₁₋₆ alkyl groups or R⁴ represents a group of formula (i) wherein f and k both represent 0, g represents 2 and R¹³ represents C₁₋₆ alkyl or C₃₋₈ cycloalkyl.

30

9. A compound as defined in claim 8 wherein R⁴ represents a group of formula (i) wherein f and k both represent 0, g represents 2 and R¹³ represents i-propyl.

35

10. A compound as defined in claim 1 which is:

4-(4-[[3-(1-Piperidiny)propyl]oxy]phenyl)-1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidine;
 4-[[4-(4-[[3-(1-Piperidiny)propyl]oxy]phenyl)-1-piperidiny]carbonyl]benzonitrile;
 40 4-[[4-(4-[[3-(1-Piperidiny)propyl]oxy]phenyl)-1-piperidiny]carbonyl]pyridine;
 4-(4-[[3-(1-Piperidiny)propyl]oxy]phenyl)-1-[[4-(1-pyrrolidiny)carbonyl]phenyl] carbonyl] piperidine;

- 1-[[4-(Methylsulfonyl)phenyl]carbonyl]-4-(4-[[3-(1-piperidiny) propyl] oxy} phenyl) piperidine;
- 1-[(4-Fluorophenyl)carbonyl]-4-(4-[[3-(1-piperidiny)propyl]oxy}phenyl)piperidine;
- 3-[[4-(4-[[3-(1-Piperidiny)propyl]oxy}phenyl)-1-piperidiny]carbonyl]pyridine;
- 5 4-[[4-(4-[[3-(1-Piperidiny)propyl]oxy}phenyl)-1-piperidiny]carbonyl]morpholine;
- 1-(1-Piperidiny)carbonyl]-4-(4-[[3-(1-piperidiny)propyl]oxy}phenyl)piperidine;
- 4-(4-[[3-(1-Piperidiny)propyl]oxy}phenyl)-1-(1-pyrrolidiny)carbonyl)piperidine;
- 1-(4-Fluoro-phenyl)-1-{4-[4-(1- isopropyl-piperidin-4-yloxy)-phenyl]-piperidin-1-yl}-methanone;
- 10 1-(1-Methylethyl)-4-[[4-(1-[[4-(1-pyrrolidiny)carbonyl]phenyl]carbonyl)-4-piperidiny]phenyl]oxy)piperidine;
- 1-(1-Methylethyl)-4-({4-[1-(tetrahydro-2*H*-pyran-4-ylcarbonyl)-4-piperidiny]phenyl}oxy)piperidine;
- 1-(1-Methylethyl)-4-[[4-(1-[[4-(methylsulfonyl)phenyl]carbonyl]-4-piperidiny]phenyl]oxy)piperidine;
- 15 1-(1-Methylethyl)-4-[(4-{1-[3-(methyloxy)propanoyl]-4-piperidiny] phenyl}oxy)piperidine;
- 4-[[4-(4-[[1-(1-Methylethyl)-4-piperidiny]oxy}phenyl)-1-piperidiny] carbonyl]pyridine;
- 3-[[4-(4-[[1-(1-Methylethyl)-4-piperidiny]oxy}phenyl)-1-piperidiny] carbonyl]pyridine;
- 4-[[4-(4-[[1-(1-Methylethyl)-4-piperidiny]oxy}phenyl)-1-piperidiny]carbonyl] morpholine;
- 20 1-(1-Azetidinylcarbonyl)-4-(4-[[1-(1-methylethyl)-4-piperidiny]oxy}phenyl) piperidine;
- 1-(1-Methylethyl)-4-({4-[1-(1-pyrrolidiny)carbonyl]-4-piperidiny] phenyl}oxy)piperidine;
- 1-(1-Methylethyl)-4-({4-[1-(1-piperidiny)carbonyl]-4-piperidiny]phenyl}oxy)piperidine;
- 4-[[4-(4-[[1-(1-Methylethyl)-4-piperidiny]oxy}phenyl)-1-piperidiny] carbonyl]thiomorpholine 1,1-dioxide;
- 25 4-[[4-(4-[[1-(Cyclobutyl-4-piperidiny)oxy] phenyl]-1-piperidiny)carbonyl] benzonitrile;
- 1-Cyclobutyl-4-[(4-{1-[(4-fluorophenyl) carbonyl]-4-piperidiny]phenyl} oxy] piperidine;
- 1-Cyclobutyl-4-[[4-(1-[[4-(1-pyrrolidiny)carbonyl]phenyl]carbonyl)-4-piperidiny]phenyl]oxy)piperidine;
- 1-Cyclobutyl-4-[(4-{1-[3-(methyloxy) propanoyl]-4-piperidiny] phenyl}oxy] piperidine;
- 30 4-[(4-{4-[[1-(Cyclobutyl-4-piperidiny)oxy] phenyl]-1-piperidiny)carbonyl]pyridine;
- 3-[(4-{4-[[1-(Cyclobutyl-4-piperidiny)oxy]phenyl]-1-piperidiny)carbonyl]pyridine;
- 4-[(4-{4-[[1-(Cyclobutyl-4-piperidiny)oxy]phenyl]-1-piperidiny)carbonyl]morpholine;
- 1-[(4-Fluorophenyl)carbonyl]-4-(4-[[3-(1-piperidiny)propyl]oxy}phenyl)-1,2,3,6-tetrahydropyridine;
- 35 4-[[4-(4-[[3-(1-Piperidiny)propyl]oxy} phenyl)-3,6-dihydro-1(2*H*)-pyridiny] carbonyl] benzonitrile;
- 4-(4-[[3-(1-Piperidiny)propyl] oxy}phenyl)-1-[[4-(1-pyrrolidiny)carbonyl]phenyl]carbonyl]-1,2,3,6-tetrahydropyridine;
- 4-(4-[[3-(1-Piperidiny)propyl] oxy} phenyl)-1-(tetrahydro-2*H*-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridine;
- 40 1-[[4-(Methylsulfonyl)phenyl]carbonyl]-4-(4-[[3-(1-piperidiny)propyl]oxy} phenyl) -1,2,3,6-tetrahydropyridine;

- 4-[[4-(4-[[3-(1-Piperidiny]propyl]oxy}phenyl)-3,6-dihydro-1(2H)-pyridiny]carbonyl]morpholine;
 1-(1-Piperidiny]carbonyl)-4-(4-[[3-(1-piperidiny]propyl]oxy}phenyl)-1,2,3,6-tetrahydropyridine;
 5 4-(4-[[3-(1-Piperidiny]propyl]oxy}phenyl)-1-(1-pyrrolidiny]carbonyl)-1,2,3,6-tetrahydropyridine;
 1-[(4-Fluorophenyl)carbonyl]-4-(4-[[1-(1-methylethyl)-4-piperidiny]oxy}phenyl)-1,2,3,6-tetrahydropyridine;
 4-[[4-(4-[[1-(1-Methylethyl)-4-piperidiny]oxy}phenyl)-3,6-dihydro-1(2H)-pyridiny]carbonyl]benzonitrile;
 10 4-(4-[[1-(1-Methylethyl)-4-piperidiny]oxy}phenyl)-1-[[4-(1-pyrrolidiny]carbonyl)phenyl]carbonyl]-1,2,3,6-tetrahydropyridine;
 4-(4-[[1-(1-Methylethyl)-4-piperidiny]oxy}phenyl)-1-(tetrahydro-2H-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridine;
 15 4-(4-[[1-(1-Methylethyl)-4-piperidiny]oxy}phenyl)-1-[[4-(methylsulfonyl)phenyl]carbonyl]-1,2,3,6-tetrahydropyridine;
 4-[[4-(4-[[1-(1-Methylethyl)-4-piperidiny]oxy}phenyl)-3,6-dihydro-1(2H)-pyridiny]carbonyl]pyridine;
 4-[[4-(4-[[1-(1-Methylethyl)-4-piperidiny]oxy}phenyl)-3,6-dihydro-1(2H)-pyridiny]carbonyl]morpholine;
 20 4-(4-[[1-(1-Methylethyl)-4-piperidiny]oxy}phenyl)-1-(1-piperidiny]carbonyl)-1,2,3,6-tetrahydropyridine;
 4-(4-[[1-(1-Methylethyl)-4-piperidiny]oxy}phenyl)-1-(1-pyrrolidiny]carbonyl)-1,2,3,6-tetrahydropyridine;
 25 4-([4-[4-[[3-[(2R)-2-Methyl-1-pyrrolidiny]propyl]oxy}phenyl]-1-piperidiny]carbonyl)benzonitrile;
 4-[4-[[3-[(2R)-2-Methyl-1-pyrrolidiny]propyl]oxy}phenyl]-1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidine;
 4-[4-[[3-[(2R,5R)-2,5-Dimethyl-1-pyrrolidiny]propyl]oxy}phenyl]-1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidine;
 30 2-[[4-(4-[[1-(1-Methylethyl)-4-piperidiny]oxy}phenyl)-1-piperidiny]carbonyl]pyrazine;
 3-[[4-(4-[[1-(1-Methylethyl)-4-piperidiny]oxy}phenyl)-1-piperidiny]carbonyl]benzonitrile;
 1-(1-Methylethyl)-4-[[4-(1-[[4-(trifluoromethyl)phenyl]carbonyl]-4-piperidiny]phenyl]oxy}piperidine;
 35 6-[[4-(4-[[1-(1-Methylethyl)-4-piperidiny]oxy}phenyl)-1-piperidiny]carbonyl]quinoxaline;
 or a pharmaceutically acceptable salt thereof.

11. A compound as defined in claim 1 which is:

- 5-[[4-(4-[[1-(1-Methylethyl)-4-piperidiny]oxy}phenyl)-1-piperidiny]carbonyl]-2-pyridinecarbonitrile; and
 40 5-[[4-(4-[[1-(1-Methylethyl)-4-piperidiny]oxy}phenyl)-1-piperidiny]carbonyl]-2-(trifluoromethyl)pyridine;

or a pharmaceutically acceptable salt thereof.

12. A compound as defined in claim 1 which is:

4-[[4-(4-[[1-(1-Methylethyl)-4-piperidinyloxy}phenyl)-1-piperidiny]] carbonyl} benzonitrile
or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition which comprises the compound of formula (I) as defined in any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

14. A compound as defined in any one of claims 1 to 12 for use in therapy.

15. A compound as defined in any one of claims 1 to 12 for use in the treatment of neurological diseases.


16. Use of a compound as defined in any one of claims 1 to 12 in the manufacture of a medicament for the treatment of neurological diseases.

17. A method of treatment of neurological diseases which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition for use in the treatment of neurological diseases which comprises the compound of formula (I) as defined in any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

19. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:

(a) preparing a compound of formula (I) wherein Z represents CO which comprises reacting a compound of formula (II)



or an optionally activated or protected derivative thereof, wherein --- , R^2 , R^3 , R^4 , m and n are as defined in claim 1, with a compound of formula $R^1\text{-CO-L}^1$, wherein R^1 is as defined in claim 1 and L^1 represents a suitable leaving group such as a suitable halogen atom, or a hydroxyl group; or

- (b) preparing a compound of formula (I) wherein Z represents SO_2 which comprises reacting a compound of formula (II), with a compound of formula $\text{R}^1\text{-SO}_2\text{-L}^2$, wherein R^1 is as defined in claim 1 and L^2 represents a suitable leaving group, such as a suitable halogen atom (eg. chlorine); or
- 5
- (c) preparing a compound of formula (I) wherein Z represents CONH which comprises reacting a compound of formula (II), with a compound of formula $\text{R}^1\text{-N=C=O}$, wherein R^1 is as defined in claim 1; or
- 10
- (d) preparing a compound of formula (I) wherein Z represents CONR^{10} which comprises reacting a compound of formula (II), with a compound of formula $\text{R}^1\text{R}^{10}\text{N-L}^3$, wherein R^1 and R^{10} are as defined in claim 1 and L^3 represents hydrogen or COCl ; or
- 15
- (e) deprotecting a compound of formula (I) or converting groups which are protected; and optionally thereafter
- (f) interconversion to other compounds of formula (I).